首页> 外文会议>International Conference on Tissue Engineering >3D scaffolds in talus chondral lesions-ACI / fibrin glue scaffold versus type I collagen / hydroxyapatite scaffold
【24h】

3D scaffolds in talus chondral lesions-ACI / fibrin glue scaffold versus type I collagen / hydroxyapatite scaffold

机译:3D Talus Chintral病变的脚手架 - ACI /纤维蛋白胶水支架与I型胶原蛋白/羟基磷灰石脚手架

获取原文

摘要

Chondral lesions do not heal in adult mature cartilage. Introduced in 1987 for large full thickness cartilage defects treatment, autologous cultured chondrocyte implantation (ACI) with cells in suspension showed promising results. With chondrografts of second and third ACI generation, the scaffold choice became the real issue. One of the disadvantages that has been pointed out about ACI procedure, is the need for a previous cartilage harvesting before implantation. In order to avoid this two-step surgery a new engineered type I collagen/ hydroxyapatite scaffold has recently been developed, which allows to address chondral lesions with a one-step procedure, laying an implant in place that will eventually be fulfilled with new cells arising form the subchondral bone. In this study we used both a 3D-solid fibrin glue scaffold with chondrocytes included inside the scaffold, and a type I collagen/ hydroxyapatite scaffold, on a number of different patients. In pre-clinical animal studies, both chondrocyte implantation using autologous cultured chondrocytes inside a solid fibrin-glue scaffold and the type I collagen/ hydroxyapatite scaffold proved to be a good solution for full thickness cartilage defects treatment. Seven patients with ages between 32 and 65 years-old were treated with either ACI or the collagen/ hydroxyapatite (HA) scaffold. All the four patients treated with ACI procedures had a clinical follow-up of more than five years, whereas the collagen/ HA scaffold patients had a mean follow-up of one and a half years. The final result seems to be age dependent. A second-look surgery was performed in two cases. In both cases it had been used the collagen/ hydroxyapatite scaffold. In one case there was a reactive synovitis and in the other an arthrofibrosis developed. In both cases arthroscopy showed complete cartilage coverage of the previous lesion. All the patients were retrospectively clinically assessed using Weber and Mazur ankle rating scales. Overall results showed good or excellent clinical results in all but one patient (85%), with 5 asymptomatic patients (72%) even in heavy work or in high sports level. The two symptomatic patients belong to the collagen/ hydroxyapatite scaffold group.
机译:Chintral病变不会在成人成熟软骨中愈合。 1987年推出的用于大型全厚软骨缺陷处理,悬浮液中具有细胞的自体培养的软骨细胞植入(ACI)显示出有前途的结果。与二次和第三委员会的软骨移植物,脚手架选择成为真正的问题。关于ACI程序指出的缺点之一是需要在植入前之前的软骨收获。为了避免这种两步手术,最近开发了一种新的工程化I型胶原蛋白/羟基磷灰石支架,其允许用一步法地处理骨性病变,将植入物放置在适当位置,最终将通过产生的新细胞实现最终实现形成子骨髓。在这项研究中,我们将3D固体纤维蛋白胶囊支架与在支架内部包含的软骨细胞,以及在许多不同患者上的I型胶原醛/羟基磷灰石支架。在临床前的动物研究中,使用固体纤维蛋白 - 胶囊中的自体培养的软骨细胞和I型胶原/羟基磷灰石支架中的软骨细胞植入证明是全厚度软骨缺陷处理的良好溶液。患有32至65岁之间的7例患者用ACI或胶原/羟基磷灰石(HA)支架治疗。所有患有ACI程序治疗的四个患者都有五年以上的临床随访,而胶原蛋白/哈哈支架患者的平均随访一年半。最终结果似乎是依赖的年龄。两种情况下进行了第二种手术。在两种情况下,它已被使用胶原醛/羟基磷灰石支架。在一种情况下,存在反应性滑膜炎,另一个是在另一个中发育的节点纤维化。在两种情况下,关节镜检查显示前病变的完全软骨覆盖。所有患者均使用Weber和Mazur Ankle评级尺度回顾性地评估。除了一个患者(85%),患者(85%),甚至在繁重的工作或高运动水平中,整体结果表明良好或优异的临床结果两个症状患者属于胶原醛/羟基磷灰石支架组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号